Reports Total Net Revenue1 of $88.2 Million, up 37% YoY, Including Record Net Revenue1 of $68.1 Million in Global Medical Cannabis, up 51% YoYGenerates Record Net Income of $31.2 Million, up 282% YoY, and Record Adjusted EBITDA1 of $23.1 Million, up 316% YoYAchieves Target of Positive Free Cash Flow1 in Q3, Generating $27.4 Million of Free Cash Flow1Maintains Strong Balance Sheet with $180 Million of Cash and Debt-Free Cannabis Business2EDMONTON, AB, Feb. 5, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results ...

BOSTON, Feb. 4, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced its Special Meeting scheduled for and convened on February 4, 2025 (the "Special Meeting") has been adjourned until February 25, 2025 at 9:30 a.m. Eastern time (the "Adjourned Special Meeting") for the purpose of soliciting additional votes with respect to the proposals outlined below and described in the Company's definitive proxy statement for the Special Meeting filed with the Securities and Exchange Commission (the "SEC") on December 30, 2024 (the "Special Meeting ...

NASHVILLE, Tenn., Feb. 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced positive top-line results from its Phase 2 FIGHT DMD trial. The study evaluated ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease – the leading cause of death in DMD patients. It marks a breakthrough for these patients, as it's the first successful Phase 2 study specifically targeting the cardiac complications of their condition.

EDINBURGH, Scotland, Feb. 5, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it will change its ratio of its American Depositary Shares ("ADSs") to ordinary shares from one (1) ADS representing two hundred (200) ordinary shares to one ADS representing four thousand (4,000) ordinary shares (the "ADS Ratio Change"). The ADS Ratio Change is expected to become effective on February 10, 2025, U.S. Eastern Time.